Coronavirus

Study results show immunoglobulin G antibodies were detected in 13 of 382 individuals in the first phase and 71 of 168 in the second, with age and vaccination status contributing factors.

Investigators at Penn State find that these medications inhibit certain viral enzymes called proteases that are essential for SARS-CoV-2 replication in infected human cells.

COVID-19 vaccines are effective in preventing severe infection resulting in hospitalization, but protection wanes after 6 months.

Although biologic changes may occur in the body that affect the brain, nonbiologic changes, such as social isolation, can also be a part of it but the reasons are not completely clear, according to the study.

As we head into March, things appear to be looking up on the COVID-19 front.

During 90 minutes of exercise, the participants focused on maintaining a pace that kept their heart race approximately 120-140 beats per minute rather than focusing on the distance.

The results of 2 analyses in the United Kingdom show a small increase in the potential for intracranial thrombosis after vaccination.

Patients from more socially vulnerable areas were sicker when they arrived at hospitals but did as well as others by the time of discharge, results of a new analysis show.

How would you respond to these patient questions?

Institute for safe medication practices receives hundreds of reports of incorrect doses for children.

Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.

Results of the analysis may help inform future COVID-19 vaccine development, investigators say.

During the period in which Omicron was the dominant variant, the researchers found that fewer patients died while hospitalized compared with those admitted when the Delta variant was dominant.

Jeff Trinkl, MD, director of clinical informatics at Epic, and Caleb Cox, data scientist at Epic, explain that only about 1.8% of patients contracted COVID-19 during a hospital stay at the highest peak of cases in December 2020.

Sachin Nagrani, MD, the medical director of Heal, discusses his predictions for the future as we continue to fight the COVID-19 pandemic.

Although prevention decreased with time, a third booster dose was still highly effective at preventing severe illness with COVID-19.

The variants include Alpha, Beta, Gamma, Delta, and Omicron, and the laboratory results are consistent with other analyses.

Sachin Nagrani, MD, the medical director of Heal, discusses what pharmacists should know about the Omicron variant and other variants popping up globally.

But results of analysis show that the positive effects of vaccination still outweigh the potential adverse events.

NVX-CoV2373 (Novavax) was found to provide 100% protection against moderate and severe disease and 90.4% efficacy overall in a phase 3 trial last year.

Sachin Nagrani, MD, the medical director of Heal, discusses Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

Adversity has disproportionately hurt certain populations, including essential workers and women, the results of a new analysis show.

The use of these services in oncology is likely here to stay.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how building resilience in the medicine supply chain will help bolster preparedness for what may arise during the COVID-19 pandemic and beyond.

Bebtelovimab gets Emergency Use Authorization to treat mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe COVID-19.

Ronald T. Piervincenzi, CEO of US Pharmacopeia, discusses how drug shortages are related to medicine quality issues.

Study shows that 98% of cases of multi-system inflammatory syndrome in children (MIS-C) were unvaccinated, suggesting that vaccination reduces the chance of a child who had COVID-19 later developing MIS-C.

Study shows that treatment with rituximab (Rituxan) for B-cell non-Hodgkin lymphoma prior to COVID-19 vaccination significantly lowered the number of patients who developed blocking antibodies for the virus.

Data suggest that omicron-specific CD8-positive T cell responses were more than 80% cross-reactive with the CD8-positive T cell response to the original strain of the virus.

Following the first 3 days after a COVID-19 diagnosis, the risk of stroke quickly decreased.